Alberta Blue Cross 2026 Pipeline: GLP-1 'Second Wave' Coming Advertisement Felix Alberta Blue Cross's 2026 drug pipeline report identifies GLP-1 receptor agonists as a continued major cost driver for private drug plans, projecting that overall GLP-1 plan spend is unlikely to decline in future years despite the arrival of generic semaglutide expected mid-2026 [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
Regarding cardiovascular parameters , clinical trials have consistently observed modest increases in resting heart rate with GLP-1 receptor agonists, typically in the range of 24 beats per minute
TrimRx cancellations go through its provider check-in process, and its 3-month results guarantee is tied to ongoing adherence
doi:10.1056/NEJMoa1501352 Rosenstock J, Perkovic V, Johansen OE, et al
Metformin, on the other hand, is more likely to cause diarrhea, abdominal cramping, and bloating
The FDA-approved prescribing information recommends gradual dose titration specifically to minimize gastrointestinal tolerability issues, allowing the digestive system time to adapt to the medication's effects on gut function
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
